Jenkins, VA, Solis-Trapala, I, Payne, H, Mason, M, Fallowfield, LJ, May, SF, Matthews, L and Catt, SL (2018) Treatment experiences, information needs, pain and quality of life in men with mCRPC: Results from the EXTREQOL study. Clinical Oncology, 31 (2). pp. 99-107. ISSN 0936-6555

[thumbnail of EXTREQOLrevised manuscriptclean version 15th Oct.pdf]
EXTREQOLrevised manuscriptclean version 15th Oct.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (212kB) | Preview


Delaying progression, ameliorating symptoms and maintaining Quality of Life (QoL) are primary aims of treatment for metastatic Castrate Resistant Prostate Cancer (mCRPC). Real world rather than clinical trial data about symptoms and side effects are sparse. In EXTREQOL patients’ QoL, pain and information needs were recorded during treatment.

Men with mCRPC from 20 UK cancer centres commencing various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.

132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate (FACT-P) mean=-3.89, 95% CI: -6.7 to -1.05, p =0.007; Trial Outcome Index analysis (TOI) mean=-3.10, 95% CI: -5.34 to -0.83, p = 0.007. Those who came off novel therapy and remained on LHRH agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale (PSC) mean difference= -4.45, 95% CI: 95% CI: -7.06 to -1.83, p-value=0.001; TOI mean difference = -5.62, 95% CI: -10.97 to -0.26, p =0.040). At 3 & 6 months men who reported
pain at baseline improved (43%; 40% respectively), but for others pain levels remained the same (45%; 42%) or worsened (13%; 18%). Information regarding supportive care was lacking throughout the period of time on the study.

Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: mCRPC, pain control, QoL, information needs, side effects
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine and Health Sciences > Primary Care Health Sciences
Depositing User: Symplectic
Date Deposited: 05 Nov 2018 11:11
Last Modified: 23 Nov 2019 01:30

Actions (login required)

View Item
View Item